SCHEMBL3737449

SCHEMBL3737449

COC(=O)c1c(C)cccc1OCCCCNC(=O)C(Cc1ccc(C(F)(F)P(=O)(O)O)cc1)NC(=O)OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 20/20 0.51
PTPN22 Q9Y2R2 5/20 0.51
PTPRF P10586 1/20 0.47
PTPN2 P17706 1/20 0.47
PTPRA P18433 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3737448 1.00 PTPN1 (0.51) PTPN1PTPN22PTPRFPTPN2PTPRA
SCHEMBL3745640 0.93 PTPN1 (0.59) PTPN1PTPN22PTPRFPTPN2PTPRA
SCHEMBL3745642 0.93 PTPN1 (0.59) PTPN1PTPN22PTPRFPTPN2PTPRA
SCHEMBL3732014 0.92 PTPN1 (0.48) PTPN1PTPN22PTPRFPTPN2PTPRA
SCHEMBL3732017 0.92 PTPN1 (0.48) PTPN1PTPN22PTPRFPTPN2PTPRA
SCHEMBL3732019 0.91 PTPN1 (0.48) PTPN1PTPN22PTPRFPTPN2PTPRA
SCHEMBL3798553 0.90 PTPN1 (0.48) PTPN1PTPN22PTPRFPTPN2PTPRA
SCHEMBL3798551 0.90 PTPN1 (0.48) PTPN1PTPN22PTPRFPTPN2PTPRA
SCHEMBL3737452 0.87 PTPN1 (0.51) PTPN1PTPN22PTPRFPTPN2PTPRA
SCHEMBL3736085 0.84 PTPN1 (0.57) PTPN1PTPN22PTPRFPTPN2PTPRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060142250-A1 Protein tyrosine phosphatase inhibitors and methods of use thereof FALCON TECHNOLOGY PARTNERS L.P. 2006-06-29 US claimed
US-7829737-B2 Protein tyrosine phosphatase inhibitors and methods of use thereof CEPTYR, INC. (US) 2010-11-09 US disclosed
US-20090131374-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CEPTYR, INC. (US) 2009-05-21 US disclosed
US-20090131374-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CEPTYR, INC. (US) 2009-05-21 US disclosed
US-20090131374-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CEPTYR, INC. (US) 2009-05-21 US disclosed
US-7504389-B2 Protein tyrosine phosphatase inhibitors and methods of use thereof CEPTYR, INC. (US) 2009-03-17 US disclosed
US-7504389-B2 Protein tyrosine phosphatase inhibitors and methods of use thereof CEPTYR, INC. (US) 2009-03-17 US disclosed
US-7504389-B2 Protein tyrosine phosphatase inhibitors and methods of use thereof CEPTYR, INC. (US) 2009-03-17 US disclosed
US-20080161592-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CEPTYR, INC. (US) 2008-07-03 US disclosed
US-20060142250-A1 Protein tyrosine phosphatase inhibitors and methods of use thereof FALCON TECHNOLOGY PARTNERS L.P. 2006-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161592-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF PPM1B, PTPN1, PTPN5 PTPN1 2/4885PTPN22 8/4885PTPRF 9/4885
US-20060142250-A1 Protein tyrosine phosphatase inhibitors and methods of use thereof PPM1B, PTPN1, PTPN5 PTPN1 2/4885PTPN22 8/4885PTPRF 9/4885
US-20090131374-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF PPM1B, PTPN1, PTPN5 PTPN1 2/4885PTPN22 8/4885PTPRF 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.